13 results about "Primary tumor" patented technology

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

This invention discloses a T-cell training method based on tumor organ-on-a-chip. The method includes: preparing an organ-on-a-chip with a micropillar array and a biomimetic fishbone structure; introducing primary tumor cells from a patient into the chip, causing them to spontaneously form uniform three-dimensional tumor spheroids; dynamically pumping pre-activated peripheral blood lymphocytes from the same patient into the chip and co-culturing them with the tumor spheroids; collecting the co-cultured lymphocytes and repeating the co-culture process multiple times to obtain a lymphocyte population with enhanced anti-tumor activity. This invention utilizes organ-on-a-chip technology to highly simulate the dynamic tumor immune microenvironment in vivo. Through multiple cycles of "training," it effectively activates and expands tumor-specific T cells, avoiding immune exhaustion, and providing a highly efficient and controllable new platform for personalized immunotherapy of solid tumors.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The application provides a bicyclic compound with a structure shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a prodrug molecule thereof, a pharmaceutical composition and application. The compound provided by the application can activate CD137, enhance the immune function of cytotoxic T lymphocytes (CTL), enhance the memory function of CD8+ T cells and CD4+ T cells, can make the polarization of CD4+ T cells tilt to a state beneficial to cellular immunity, and can promote the multimerization of CD137, so that T cell immunity can be effectively activated, the volume of a primary tumor can be effectively reduced, and the compound can be used for inhibiting and treating tumors.

This invention discloses a method and application for constructing personalized organoids for multiple myeloma based on stiffness gradient regulation, belonging to the field of biomedical technology. The method includes the following steps: S1: mixing patient bone marrow plasma with a calcium-containing crosslinking agent to form a gelatable precursor; S2: combining the gelatable precursor with a three-dimensional gelatin scaffold having a stiffness gradient (Young's modulus of 25-50 kPa) to construct a three-dimensional microenvironment simulating the stiffness gradient of bone marrow; S3: gelling the precursor to form a hydrogel-scaffold composite system encapsulating target cells; S4: seeding vascular endothelial cells onto the surface of the composite system to simulate a vascular niche structure. The organoid model for multiple myeloma constructed by this invention, based on the patient's autologous bone marrow plasma and possessing stiffness gradient characteristics, can effectively simulate the bone marrow mechanical microenvironment and preserve key components of the tumor microenvironment, supporting the long-term growth of primary tumor cells and improving the accuracy of drug sensitivity prediction.

The present application relates to the technical field of rectal cancer CTV segmentation, in particular to a rectal cancer CTV segmentation method based on CViL-UNet, comprising the following steps: preprocessing rectal cancer CT image data, converting a 3D CT sequence into a multi-channel 2D input format, removing image noise and intensity non-uniformity, and standardizing the pixel value range to adapt to the CViL-UNet model input. The present application realizes accurate identification of the key areas of CTV primary tumor, subclinical spread area and micro-infiltration focus through local-global feature cooperation and high-frequency detail enhancement, solves the pain points of missing micro-infiltration and misjudging healthy tissue in traditional methods, can process conventional CT images without intestinal preparation, breaks the dependence of traditional methods on ideal image conditions, and the automatic and real-time segmentation process in clinical value eliminates the subjectivity and inefficiency caused by manual intervention, while meeting the dual requirements of millimeter-level precision and rapid deployment for radiotherapy planning.

This invention relates to an animal model of mediastinal lymph node metastasis in lung cancer and its construction method. The core of this invention lies in the precise intrapulmonary in situ microinjection technique to directly implant human lung cancer cells into the lung parenchyma of immunodeficient mice. Utilizing the natural lymphatic drainage pathway of the lung tissue, tumor cells are induced to migrate to the mediastinal lymph nodes, thus successfully constructing a complete metastasis chain model from the primary tumor to regional lymph nodes. This model can more realistically simulate the microenvironment and process of lung cancer lymph node metastasis, and is suitable for metastasis mechanism research, drug evaluation, and the development of personalized treatment strategies, possessing high translational medicine value.

This invention relates to the field of artificial intelligence in oncology medicine, specifically disclosing a system for quantifying residual tumor burden in gastric cancer, comprising: a data acquisition and interaction terminal, an AI core computing center, and a clinical precision decision support platform; the data acquisition and interaction terminal is configured to acquire in parallel high-resolution digital pathological slides of patients after surgery, continuous physiological time-series characteristic sequences after surgery, and the molecular expression abundance of POU4F1 transcription factor and TGF-β signaling pathway in tumor tissue; the AI ​​core computing center includes a three-dimensional quantification unit for pathological images, a dynamic correction unit for physiological homeostasis, and a molecular phenotypic decision unit; the three-dimensional quantification unit for pathological images is used to automatically segment and obtain the geometric mean diameter of the primary tumor bed, the proportion of residual tumor in the primary lesion, the number of positive lymph nodes, and the proportion of residual tumor in the worst-regressed lymph nodes; the technical solution of this invention can solve the problems of coarse quantification and large subjective bias.

This invention provides a stable passaged human mesothelioma cell line MESO-016, its construction method, and its application in tumor research and drug development. The cell line provided by this invention can be continuously passaged in vitro and possesses xenogeneic tumorigenesis ability. Tumors formed in nude mice exhibit the same pathological characteristics as the primary tumor tissue, making it suitable as a cell material for research on mesothelioma-related drugs and diagnostic reagents, as well as for studying the mechanisms of tumor development and progression.

The application discloses a kind of mannose modified graphene oxide-based nano drug delivery systems and its preparation method and application, belong to the technical field of biomedical materials and pharmaceutical preparations.The application solves the current free drug in vivo exposure shortage, lack of myeloid cell directional regulation, drug release uncontrollable and drug system biological compatibility problem.The application synthesizes mannose grafted ethylenediamine EDM, then with GO, EDM, EDC and NHS reaction, promote GO surface carboxyl and EDM amino form amide bond, obtain carrier, with DTX and Vadimezan loaded on carrier to obtain drug delivery system.The application uses GO as matrix, realizes receptor-mediated targeting nano-carrier system by surface functionalization of mannose, and it is used to deliver hydrophobic chemotherapeutic drugs and immune stimulants, which can be used for tumor treatment, including inhibiting primary tumor growth and metastasis-related lesions, and the effect is more obvious in combination with near-infrared light thermal response.

The present invention relates to an OLFML2B biomarker for treatment of hepatocellular carcinoma and prediction of recurrence, and use thereof. Specifically, OLFML2B exhibits a high AUC in hepatocellular carcinoma diagnostic performance and is more useful for predicting recurrence, and has been identified to have consistent performance in various public data such as MDACC and GSE series. In Cox regression analysis, OLFML2B has been identified to be a significant factor in survival and recurrence, and has shown a more distinct increase in expression in malignant hepatocytes, PVTT, and recurrent tumor tissue than in normal tissue or primary tumor. In addition, it has been identified that the invasiveness and proliferation of hepatocellular carcinoma cell lines are significantly reduced when OLFML2B is inhibited. Therefore, the present invention can ultimately promote an improvement in survival rate and treatment outcomes of hepatocellular carcinoma patients.